Kalaris Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2024
Filed with the SEC on May 13, 2024 and accepted by EDGAR at May 13, 2024, 16:00 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2024-01-01 to 2024-03-31 | $12.2m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2024-01-01 to 2024-03-31 | −$32.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-01-01 to 2024-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-01-01 to 2024-03-31 | −$30.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-01-01 to 2024-03-31 | −$0.26 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-01-01 to 2024-03-31 | −$0.26 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-01-01 to 2024-03-31 | 114,690,726 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2024-01-01 to 2024-03-31 | −$44.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2024-03-31 | $86.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-03-31 | $141.5m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-03-31 | $144.1m | us-gaap:Assets |
| Current liabilities | At period end2024-03-31 | $7.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-03-31 | $23.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2024-03-31 | $120.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-058607. Last ingested by Listed: Oct 26, 2026, 17:31 ET. Listed shows no prices and gives no investment advice.